 Good morning everyone, it is a 4th for Thai time, it's 1.30 in the morning, okay? So I have the opportunity to talk to you about what we have achieved for the last 10 years and look at this girl, which she has a special type of pigtail, double helix. So after everyone, we have the industrial evolution, not revolution, okay? And then we have the machine, we place manpower and the animal power. So we have a lot of grain and meat. So our skyrocket of human population is now rising. We have 1 billion now every 12 years. So in our country, we believe, and like in the other countries, believe that the genomic evolution should be part of the maintain the mankind for feed and treat, okay? Particularly the micro plant animals and humans. This is the major event in Thai genome project, start from 1997. We have the Thai Genomic Roadmap in 1998. We have the first call of bifematic teaching in university in 1999. We have the medical molecular biology, especially mostly in the university hospital. And by this one, we prove to the public that, particularly for the HIV, we do a lot of the medication, CD4, water load and HV genotype drug resistance, as say. And now in the past, we have to pay about 5 billion, 5 billion Thai baht per year for taking care of HIV. We have about 1 million people who are infected with the HIV, but now we have only 5,000 new cases. Now we're getting to zero and we're working well. That's why this one, like we convince the public and also the government that somehow we need to invest to pay less in the future. And for the Bacteria Genome, 1999, we have Bucary Suburbaniai sequence. And for 2002, we have the Wright Genome Project. And now we have many crops that tolerate the global warming effect in Thailand. 2002, we have what we call Thai SNP. We collaborate with the French government to sequence some certain genes and have our variant compared to other. In 2005, after the APEC meeting, 2003, we have what we call the Pharmacogenome Project. And then we have the second phase of the Thai SNP, sorry, we call the Thai Pat agent SNP by comparing the SNP, Thai SNP, with the Southeast Asian country, 2011. We have the complete genome sequence of the Thai male. 2013, we think that we estimate what we call the Medical Genomic Center. It is a small one. We like a prototype for the government to implement throughout the country. In 2014 this year, I think that we are going toward what we call democratization of the sequencing, because everyone nearly has the opportunity to have their own part of the genome sequence. And now the price should be dropped down if we can work out with the MSIME instead of doing an exome 408 coverage, if we can do at five coverage when more can sequence. So let's talk about the pharmacogenomics. Because in the past, the government would like Thailand to leapfrog strategy, meaning to be upfront in the Thailand life sign innovation. So after the APEC meeting, we have the conclusion that Thailand should have the organization called T-SEL, Thailand Center for Life Signs. T-SEL supports the generic medicine, and the first one that they support for the last six years is pharmacogenomics. Everything that come out from that pharmacogenomics, the universal head cat coverage scheme in Thailand will be made use of that. We have a very nice, the UC system is quite different from other countries, meaning that they're nearly, most of our population is covered by the UC. And you can go to the hospital, and most of the medical expedition could be taken care of. And for the pharmacogenomics, it's now being accepted by the public and the government because we are developing countries, surprisingly, because the choice of the selection of medication is low. So we do not have much medication to choose. That's why even they have the psoriasis effect, somehow we need to have the test first, and then we can select that, okay, the 80% still can use that medication. 20% should be replaced by maybe more expensive drug. We have the organization we call Hi-Tab, and this is an independent body that we will study to call it FICTIB NEST. Everything that we've proved by this organization, the UC will follow. And now, within a 20-year time, now we can say that in Thailand, the genetic testing in humans is the amount of technology of interest by Thai public and the government. We have to handle, probably I have to go to the TV station many, many times to make sure that we have the right attitude toward the genetic testing because we need to handle that in the past on the GMO, and the GMO would now become really bad work in Thai. If you mention about GMO, then you never get the funding. And we have the collaborator. I work in the university hospital with the cross-leaf monitor and join hand with the Thai Ministry of Public Health. That is a recommendation, so we're sitting over there. And also we have the also collaboration with the Lincoln CGM. They are very nice, starting from Professor Nakamura, Jessica Nakamura, and to Professor Kubo. They also be nice to us. We do a lot of the HIV typing, GWAS, and the sequence, nearly 3,000 cases of the first type of adverse reaction. And we just realized recently that our country, particularly in Southeast Asia, we are more or less like a hotspot. You can see that from the HIV aid, mostly the adverse reaction, Thailand and Indonesia and Southeast Asia, it's more or less like a hotspot to rate one. More than 20%, we have the psoriasis effect if you're taking that kind of medication. That's why I tell you that somehow we have to manage all of those medications. This is also for aloe perinone or red. For the Neuropean, also orange. And for Lipotysphal 5D40, and we also have a lot of people suffer. And the Bacovia. We are talking about the serious like Stephen Jones syndrome in 10. And this is the list of the government from the Thai FDA. You can see that among 10 lists, the first list, because of our project and with the kind of support from the Likin, we now sort of have a marker of nearly all of these medications. And you can consider that this is all the very old medications but we have to use. We still have to use it. We have to test it first and then you follow that if you are quite free from the psoriasis effect. We are doing a lot of things like GWAS for the very huge HIV critical trial about the 2,000 people if you're infected. All the marker and everything. And then we join hand with the Rican Genesis. These are the companies spun off from the Rican to come up with, they invent the molecular-poor care device and then with the marker that we found, we somehow now have the Likin chip that can use only one drop of the blood and you can have the data, I mean the report, print it out for the clinician. We then come up with the recommendation and guidelines and everything. And also, the best of all is the UC scheme well adopted of a finding. You can see that we have many awards for the innovation and the public is really going to have accept this kind of genetic testing. And the pricing is lower. We can do maybe 10 clicks from information about 30 U.S. dollars. And this is all the recommendation that happened. And this is what the UC system adopted in Thailand. Now everyone can do the campanus spin and have the test at first. Unfortunately, this morning it just realized the HIV-15 COO instead of only for the campanus spin is also for antiretroviral drug as well. That is like healing two birds with one stone. Fortunately, we have the data published first and then we tell you what kind of antiretroviral drug. And we have the organization and for the pharmacogenomic, we have the pharmacogenomic card now for everyone. And then when they go to the clinician we have the pharmacogenomic card. Either the doctor is quite interested in anything they call a SPAC. And this is what we have in the... We have the C-farm solution. And you can see who is there. And then he is in between the taller one. And he has an idea that you should modify your natural drug list according to the genomics and we adopt that kind of idea and working out very fast for that. And we have like a meeting, 2013 and 2014. And we do the sequence and we realize that Thailand is quite different from even our close friends like Kasein, a Chinese, a Chinese in Korea. Even though they're really willing to give us the information, we cannot. So we have to have our own sequence. And the pricing is going down. We have to go fast. It is like a role model for Thailand. For the Ramartibli Hospital, we perform their genotyping. This is our facility. We have everything, a little bit of itch. Time is out. And then this is what we are currently doing. You can read it by yourself. And you can read it by yourself. Sorry. We do everything. And the people now, it's quite fascinating that all of the clinicians in the past, the last six years, when they said, we serve without full of commercial genomics, they said no. But now everyone volunteer. It is quite different from now. And they do it for inspiration instead of the motivation. And then the last one, here's the summary. One, our capacity of genomic medicine is small for countryside Thailand. We need training and capacity of building. Majority mostly for the genetic counseling and bioinformatics. And we also provide with a unique genetic diversity I already told you. And universal healthcare coverage will be ready in function. Any technology that proved to be cost effective can be considered into UC as well. Very easily. Pharmacogenomics study is unique that we have direct access to Thai FDA. It's very good. And also the Thai MOPH. Neonatal screening program, I didn't tell you much, thank you. Mark Williams, Geisinger. I was really impressed by the list of the Stevens-Johnson syndrome and TENS. I think that you have a lot more information than the rest of us have relating to potential predisposing genomic markers. Are all of those predisposing factors in the HLA region or are there other genes that have been identified that are playing a role in this particular type of cutaneous reaction? And are you planning or have you published the genomic information relating to that table? Yes. We have many publications on that about 20. And we are willing to share the data with everyone in this room. Thank you. I wanted to ask you about the pharmacogenetics card that you showed us. It went by fast, so I may have misunderstood because everybody have or is it anticipated that every tie will have one of these cards with a full pharmacogenetic profile on it? And if so, who's actually paying for that program? At first, I like to impress you all that we have the pharmacogenetic card, but actually it's just one hospital. Like a pilot project somehow and all written because in the tie ID only but globe is not enough. And the who pay for that, now the government pay for that. The people who enroll in the pharmacogenetic card. So this is a pilot project that will demonstrate the value of that particular program and if it shows that there is value it will be expanded to a TV channel. Every time that we put everything on the TV 65 million we will see and then it will come right away. Once the rheumatibility have that any hospital need to have that too. Sort of like a competition I don't know. So it rather try to convince government maybe somehow show it in the public and the public will go back to the government much easier. The card is like what you, when we do the HRA typing they all have the HRA whatever you have and then what you have a great potential to have the adverse reaction. Among the tie among the top 10 mostly. So it's just for students? First it's for students right now.